Exhibit 20

Document produced natively
TEVA-MDL2875-00001350
CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER
pdr-ele-impu-risk.pdf
ANDA\091519 Submissions\Submissions\eCTD\091519\0042\m3\32-body-data\32p-drug-prod\valsartan-and-hydrochlorothiazide-tablets-all-strengths\32p2-pharm-dev\4202596B0BEE4761C41A1ECAFA898190

Arrow Pharm (Malta) Ltd.

Title: Quality Risk Assessment of Elemental Impurities in the finished dosage form for Valsartan Hydrochlorothiazide Tablets.

RISK ASSESSMENT STUDY (RM-079)

Quality Risk Assessment of Elemental Impurities (ICH Q 3D) in the finished dosage form for Valsartan Hydrochlorothiazide Tablets.

3.2.P.2 ELEMENTAL IMPURITIES INITIAL RISK ASSESSMENT REPORT

TEVA | Actavis GENERICS	**Valsartan Hydrochlorothiazide Tablets, 80/12.5mg, 160/12.5mg, 160/25mg, 320/12.5mg and 320/25mg**
	Risk Assessment Report: RM-079

Prepared By: [redacted] Date: 25 July 17

[redacted]
Senior Quality Control Analyst

Reviewed [redacted] Date: 25th July 2017

Quality Control Supervisor

Approv[redacted] Date: 27 JUL 2017

Quality Systems Manager

Approve[redacted] Date: 2-Aug-2017

Production and Process
Validation Manager

Approved[redacted] Date: 03 Aug 2017

Quality Assurance Manager/QP